Citigroup maintains Stevanato Group at Buy, lowers price target to $20 from $26

UBS kept Stevanato Group at Neutral but cut its price target to $16 from $23, a 30.4% reduction. This implies a 19.0% upside from the Nov 4 close of $13.44.

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.